{"id":"W1042476336","doi":"10.1001/jama.297.1.43","title":"Pexelizumab for Acute ST-Elevation Myocardial Infarction in Patients Undergoing Primary Percutaneous Coronary Intervention","year":2007,"lang":"en","type":"article","venue":"JAMA","topic":"Atherosclerosis and Cardiovascular Diseases","field":"Immunology and Microbiology","cited_by":440,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Duke Clinical Research Institute; University of Alberta","keywords":"Medicine; Conventional PCI; Percutaneous coronary intervention; Cardiogenic shock; Myocardial infarction; Placebo; Internal medicine; Clinical endpoint; Heart failure; Cardiology; Bolus (digestion); Randomized controlled trial","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.007720354263948327,"score_gpt":0.2353660507162013,"score_spread":0.227645696452253,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}